Aakaar Medical

Why is Aakaar Medical Technologies Ltd falling/rising?

As of 18-Jul, Aakaar Medical Technologies Ltd's stock price is rising to 72.00, up 1.41%. This increase is driven by strong short-term performance, outperforming the Sensex, and trading above key moving averages, despite a decline in investor participation.

As of 18-Jul, Aakaar Medical Technologies Ltd's stock price is rising, currently at 72.00, reflecting a change of 1.0 (1.41%) upward. This increase can be attributed to several factors. Over the past week, the stock has outperformed the benchmark Sensex, gaining 11.80% compared to the Sensex's 0.53%. Additionally, the stock is trading above its moving averages across various time frames, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages, indicating a strong upward trend in its price.<BR><BR>Despite a decline in investor participation, with delivery volume falling by 58.33% against the 5-day average, the stock's performance today has outpaced its sector by 2.82%. This suggests that, while there may be reduced trading activity, the existing investors are still confident in the stock's potential, contributing to its rising price. Overall, the combination of strong short-term performance and favorable moving averages supports the current upward movement in Aakaar Medical Technologies Ltd's stock price.

Which are the latest news on Aakaar Medical?

What does Aakaar Medical do?

Aakaar Medical Technologies Ltd is a micro-cap company in the healthcare services industry, with a market cap of INR 94 Cr. It has no reported sales or profits, a P/E ratio of 14.00, and a return on equity of 12.17%.

Overview: <BR>Aakaar Medical Technologies Ltd operates in the healthcare services industry and is categorized as a micro-cap company.<BR><BR>History: <BR>No specific details regarding the incorporation year or status changes are available. Additionally, there are no reported sales or profit figures for any recent quarter.<BR><BR>Financial Snapshot: <BR>Most recent Net Sales: N/A <BR>Most recent Net Profit: N/A <BR>Market-cap value: INR 94 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 14.00 <BR>Industry P/E: 34 <BR>Dividend Yield: 0.00% <BR>Debt-Equity: 0.04 <BR>Return on Equity: 12.17% <BR>Price-to-Book: 1.73<BR><BR>Contact Details: <BR>Registrar Address: Not available. <BR>Phone: N/A <BR>Email: N/A <BR>Website: N/A

Who are the peers of the Aakaar Medical?

Aakaar Medical's peers include Bilcare, Aspira Pathlab, Star Imaging, Choksi Laborator, Jeevan Scienti., Royal Sense, and Shree Pacetronix. Aakaar Medical has good management risk and growth, with a recent 1-month return of 16.91%, while its six-month return is -14.47%.

Peers: The peers of Aakaar Medical are Bilcare, Aspira Pathlab, Star Imaging, Choksi Laborator, Jeevan Scienti., Royal Sense, and Shree Pacetronix.<BR><BR>Quality Snapshot: Excellent management risk is observed at Star Imaging, Royal Sense, and Shree Pacetronix, while Good management risk is found at Aakaar Medical. Below Average management risk is present at Bilcare, Aspira Pathlab, Choksi Laborator, Jeevan Scienti., and the rest. Growth is Excellent at Royal Sense, Good at Aakaar Medical, Star Imaging, and Shree Pacetronix, while Below Average growth is seen at Bilcare, Aspira Pathlab, and the rest. Average capital structure is found at Aspira Pathlab and Jeevan Scienti., while Below Average capital structure is present at Bilcare, Choksi Laborator, and the rest.<BR><BR>Return Snapshot: Aakaar Medical has a 1-year return of N/A, while the peer with the highest return is Aakaar Medical with a 1-month return of 16.91%, and the peer with the lowest return is Bilcare with a 1-year return of N/A. Additionally, Aakaar Medical's six-month return is negative at -14.47%.

Is Aakaar Medical overvalued or undervalued?

As of November 17, 2025, Aakaar Medical is considered overvalued with a PE ratio of 18.23 and an EV to EBITDA ratio of 12.87, despite being lower than some peers like Sun Pharma and Divi's Lab, while its recent stock performance has underperformed the Sensex with returns of -3.24% over the past week and -11.37% over the past month.

As of 17 November 2025, Aakaar Medical's valuation grade has moved from very expensive to expensive. The company is currently considered overvalued based on its financial metrics. The PE ratio stands at 18.23, while the EV to EBITDA ratio is 12.87, and the ROCE is 15.34%. <BR><BR>In comparison to its peers, Aakaar Medical's PE ratio is significantly lower than that of Sun Pharma, which has a PE of 36.69, and Divi's Lab, which is at 69.78. However, it is higher than some peers like Dr. Reddy's Labs, which has a PE of 17.98. The recent performance shows that Aakaar Medical has underperformed the Sensex over the past week and month, with stock returns of -3.24% and -11.37%, respectively, reinforcing the notion of its overvaluation.